Status:
COMPLETED
Effectiveness of a Digital Therapeutic on Type 2 Diabetes
Lead Sponsor:
FareWell
Conditions:
Type2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A clinical study evaluating a three month digitally delivered lifestyle change program in adults with Type 2 Diabetes. The FareWell Program (the "Program") aims to reduce well-established biomarkers o...
Detailed Description
The Program aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. It includes meal planning tools, smart shopping lists, recipes curated by a physician, diet...
Eligibility Criteria
Inclusion
- diagnosis of type 2 diabetes
Exclusion
- Inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend English.
- Does not have a smartphone (either an iPhone or Android phone)
Key Trial Info
Start Date :
July 26 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2018
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT03369626
Start Date
July 26 2017
End Date
February 28 2018
Last Update
August 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
FareWell LLC
San Francisco, California, United States, 94108